Lev Pharmaceuticals’ Hereditary Angioedema Therapy Cinryze Could Reach Market In Early 2008
Second-generation C1 inhibitor has “tremendous body of safety and efficacy data” behind it from decades of use in Europe, CEO tells “The Pink Sheet” DAILY.
Second-generation C1 inhibitor has “tremendous body of safety and efficacy data” behind it from decades of use in Europe, CEO tells “The Pink Sheet” DAILY.